Edwards Lifesciences (NYSE: EW) and Medtronic (NYSE: MDT) are among the medtech companies praising CMS’s decision to expand Medicare coverage for TAVR to people with asymptomatic severe aortic stenosis. The finalized national coverage decision, published yesterday evening, also removes the evidence development (CED) requirement for symptomatic … [Read more...] about Edwards Lifesciences, Medtronic score CMS win over TAVR
Edwards Lifesciences
12 things you need to know about the transcatheter heart valves market
Transcatheter heart valve repair and replacement have reshaped how structural heart disease is treated, and the market behind these technologies is evolving just as quickly. As valve design improves, delivery systems become more refined, and patient eligibility expands, transcatheter therapies are moving from niche alternatives to standard of … [Read more...] about 12 things you need to know about the transcatheter heart valves market
Transcatheter heart valves market to enjoy solid growth
The global, multibillion-dollar transcatheter heart valves market will grow at an 8.4% CAGR over the rest of the decade, according to MassDevice's latest Medtech Market Intelligence Report. Minimally invasive therapies have gained traction in the management of structural heart disease, and the field continues to evolve. The most established … [Read more...] about Transcatheter heart valves market to enjoy solid growth
Edwards recalls certain arterial cannula devices
The FDA today issued a notice warning of a recall of arterial perfusion cannula devices made by Edwards Lifesciences (NYSE: EW). Edwards offers its arterial perfusion cannulae for adult patients undergoing cardiopulmonary bypass. They provide arterial perfusion of oxygenated blood in the extracorporeal circuit for up to six hours. The company … [Read more...] about Edwards recalls certain arterial cannula devices
Edwards launches Sapien 3 valve with Alterra prestent in Europe
Edwards Lifesciences (NYSE:EW) announced that it launched its Sapien 3 transcatheter pulmonary valve implant (TPVI) system with Alterra adaptive prestent in Europe. The launch expands the continent’s minimally invasive treatment options to a broader range of patients with congenital heart conditions. Edwards recently received CE mark for … [Read more...] about Edwards launches Sapien 3 valve with Alterra prestent in Europe
The biggest cardiovascular stories from TCT 2023
Every year, some of the biggest names in cardiovascular technologies come together in one place for TCT. This year's 35th edition of the Transcatheter Cardiovascular Therapeutics annual scientific symposium was no different in San Francisco. Usual suspects like Medtronic and Abbott had data on display for a range of products, while other big … [Read more...] about The biggest cardiovascular stories from TCT 2023
The 24 best medical device innovations of 2022
The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products … [Read more...] about The 24 best medical device innovations of 2022
FDA approves Edwards Lifesciences’ tissue valve replacement for heart’s mitral position
Edwards Lifesciences (NYSE:EW) announced today that the FDA approved its Mitris Resilia tissue valve replacement system. Irvine, California-based Edwards designed the Mitris Resilia valve with a saddle-shaped sewing cuff that mimics the asymmetric shape of the native mitral valve. It features a low-profile frame for avoiding obstruction of the … [Read more...] about FDA approves Edwards Lifesciences’ tissue valve replacement for heart’s mitral position
Edwards touts trial results for Evoque transcatheter tricuspid valve replacement system
Edwards Lifesciences (NYSE:EW) shared data from a clinical trial showing that its Evoque transcatheter tricuspid valve replacement offers favorable patient outcomes. Irvine, California–based Edwards presented the data during the late-breaking clinical science session at the 33rd Transcatheter Cardiovascular Therapeutics (TCT), according to a … [Read more...] about Edwards touts trial results for Evoque transcatheter tricuspid valve replacement system
Sapien 3 TAVR offers improved outcomes, reduced cost, Edwards Lifesciences says
Edwards Lifesciences (NYSE:EW) today touted a cost-effectiveness analysis that supports transcatheter aortic valve replacement (TAVR) with the Sapien 3. Irvine, California-based Edwards presented data from the Partner 3 trial during the late-breaking clinical trials at the 33rd Transcatheter Cardiovascular Therapeutics (TCT), the annual … [Read more...] about Sapien 3 TAVR offers improved outcomes, reduced cost, Edwards Lifesciences says
